Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Summary

RATIONALE: Monoclonal antibodies, such as alemtuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying how well alemtuzumab works in treating patients with Waldenstrom's macroglobulinemia.

Timeline

Start

2004-01

Primary completion

—

Completion

—

Drugs

Indications